Alkem Laboratories Q1 FY27 net profit drops 22% to ₹520 crore despite revenue surge
Synopsis
Alkem Laboratories posted a 22% profit drop in Q1 FY27 — not because its business faltered, but because its tax bill nearly doubled year-on-year to ₹251 crore. Revenue grew 10.9%, EBITDA margins expanded, and both India and international sales outperformed. The headline loss masks an operationally stronger quarter than the numbers first suggest.
Key Takeaways
Alkem Laboratories reported a 21.7% YoY decline in net profit to ₹520 crore in Q1 FY27 , down from ₹664 crore in Q1 FY26.
Revenue from operations rose 10.9% to ₹3,740 crore , driven by both domestic and international growth.
India sales grew 10.3% to ₹2,497.8 crore ; international sales climbed 16% to ₹1,222.3 crore .
EBITDA rose 16.2% to ₹766.6 crore ; EBITDA margin expanded to 20.5% from 19.6% .
The profit decline was primarily driven by a near-doubling of tax expense to ₹251 crore from ₹103 crore a year ago.
MD Sandeep Singh flagged investments in R&D, MedTech, and Biotech as part of the company's next growth phase.
Alkem Laboratories reported a 21.7 per cent year-on-year decline in consolidated net profit for the first quarter of FY27 (Q1 FY27), with bottom-line growth weighed down by a sharp spike in tax expenses even as revenues and operating margins held firm. The Mumbai-based drugmaker posted a net profit of ₹520 crore in Q1 FY27, against ₹664 crore in the same quarter a year ago, according to its stock exchange filing.
Revenue and Operating Performance
Despite the profit dip, Alkem's revenue from operations climbed 10.9 per cent year-on-year to ₹3,740 crore, up from ₹3,371 crore in Q1 FY26. At the operating level, the company delivered a healthy showing: EBITDA rose 16.2 per cent to ₹766.6 crore from ₹660 crore in the year-ago period, while EBITDA margin expanded to 20.5 per cent from 19.6 per cent — signalling that core business efficiency improved even as the headline profit number fell.
India and International Business Growth
Growth was broad-based across geographies. India sales rose 10.3 per cent to ₹2,497.8 crore, with the domestic business reportedly outperforming the wider pharmaceutical market. International sales outpaced domestic growth, climbing 16 per cent to ₹1,222.3 crore, driven by strong momentum in non-US international markets.
Tax Surge Weighs on Net Profit
The primary drag on net profit was a near-doubling of the company's tax expense. Tax outgo surged to ₹251 crore in Q1 FY27, compared with just ₹103 crore in Q1 FY26 — an increase of roughly ₹148 crore year-on-year. This single factor largely explains the gap between robust operating performance and the reported profit decline, a distinction that analysts tracking the stock would be expected to note.
What the Management Said
Managing Director Sandeep Singh said the company had begun FY27 on a steady note. 'We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging,' Singh said. He also acknowledged areas requiring improvement: 'At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses.' Singh further noted that Alkem is investing in R&D, MedTech, and Biotech as it builds its next phase of growth, with a focus on strengthening the core and pursuing newer opportunities 'in a disciplined manner.'
What to Watch
With operating metrics trending positively and international momentum building, the key variable for the rest of FY27 will be whether the elevated tax burden normalises and whether Alkem can sustain its market outperformance in India. Progress on regulatory and operational priorities — flagged by Singh himself — will also be closely tracked by investors.
Point of View
Not an operating one — and that distinction matters. EBITDA grew 16%, margins expanded, and both domestic and international businesses outperformed. Yet the headline number will dominate coverage. Investors should note that a near-doubling of tax expense from ₹103 crore to ₹251 crore is the real story, and whether that reflects a one-time adjustment or a structural shift in effective tax rate is the question that Q2 results will answer. Alkem's candid acknowledgement of execution gaps and regulatory priorities is also notable — it signals management is managing expectations ahead of what could be a demanding second half.
NationPress
14 Aug 2026
Frequently Asked Questions
Why did Alkem Laboratories' net profit fall in Q1 FY27?
Alkem's net profit fell 21.7% to ₹520 crore in Q1 FY27 primarily because its tax expense nearly doubled to ₹251 crore from ₹103 crore in Q1 FY26. Underlying operating performance was healthy, with EBITDA rising 16.2% and revenue growing 10.9%.
What was Alkem Laboratories' revenue in Q1 FY27?
Alkem reported revenue from operations of ₹3,740 crore in Q1 FY27, a 10.9% increase from ₹3,371 crore in the same quarter of the previous year.
How did Alkem's India and international businesses perform?
India sales rose 10.3% to ₹2,497.8 crore, with the domestic business reportedly outperforming the broader pharmaceutical market. International sales grew faster at 16%, reaching ₹1,222.3 crore, led by strong momentum in non-US markets.
What is Alkem Laboratories investing in for future growth?
Managing Director Sandeep Singh said Alkem is investing in R&D, MedTech, and Biotech as part of its next growth phase. The company aims to strengthen its core business while pursuing these newer opportunities in a disciplined manner.
What were Alkem's EBITDA and margin figures for Q1 FY27?
Alkem's EBITDA rose 16.2% year-on-year to ₹766.6 crore in Q1 FY27, with EBITDA margin improving to 20.5% from 19.6% in the same quarter last year, indicating stronger operational efficiency.
